Introduction
Proliferation, differentiation, and survival of normal cutaneous melanocytes are tightly controlled by exogenous growth factors, including basic fibroblast growth factor (bFGF/FGF-2), stem cell factor (SCF), hepatocyte growth factor (HGF), melanocyte stimulating hormone, and endothelins. These growth factors are produced by neighboring stromal cells in the skin, such as keratinocytes and fibroblasts (Halaban, 2000) . The malignant transformation of melanocytes is associated with loss of growth factor-mediated growth control, which may be achieved by changes in the expression levels of growth factor ligands or their cognate receptors, or by oncogenic activation of key components of mitogenic pathways. Hence, melanoma cells express bFGF and HGF (Albino et al., 1991; Halaban, 1996; Otsuka et al., 1998; Li et al., 2001) , and upregulate the expression of receptor protein tyrosine kinases, including ephrins (EPH-A2 and EPH-B3), the bFGF receptor (FGFR-1), and, according to some reports, the HGF receptor (c-MET) (reviewed by Easty and Bennett, 2000) . UV irradiation, the main risk factor for melanoma development, may affect the proliferation of melanocytic cells by increasing the expression of cytokines and growth factors in the skin. UVB stimulates the expression of endothelin-1 (ET-1) in cultured keratinocytes (Imokawa et al., 1992) and the expression of bFGF by epidermal fibroblasts in the murine skin in vivo (Bielenberg et al., 1998) .
Mitogenic signaling by bFGF, HGF, SCF, and endothelins occurs, at least in part, through the RAS-RAF-MEK-ERK signaling cascade (Peyssonnaux and Eychene, 2001; Smalley, 2003) . Consistent with a role of this pathway in the malignant transformation of melanocytes, oncogenic mutations in the B-RAF and NRAS genes have been found with high frequency in melanoma. Activating mutations of B-RAF, encoding the serine/threonine kinase B-RAF, have been found in roughly 75% of malignant melanoma cell lines, 60% of melanoma biopsies, and 80% of progressed nevi (Davies et al., 2002; Dong et al., 2003; Gorden et al., 2003; Pollock et al., 2003) . Notably, a single thymidine to adenosine transversion at nucleotide position 1799 accounts for 80% of the mutated B-RAF alleles. This mutation, p.V600E, which was originally mis-assigned as p.V599E/c.1796T>A (Davies et al., 2002; Kumar et al., 2003) , replaces a valine with a negatively charged glutamic acid residue in the kinase activation segment of B-RAF, and produces a higher level of kinase activity by destabilizing the hydrophobic interactions that normally preserve the inactive state of B-RAF (Wan et al., 2004) . When overexpressed, V600E B-RAF stimulated phosphorylation of ERK in COS cells and increased the focusforming ability and tumorigenicity of NIH3T3 cells (Davies et al., 2002) . In immortalized murine melanocytes, the ectopic expression of V600E B-RAF induced ERK phosphorylation, transformation and increased tumorigenicity (Wellbrock et al., 2004b) , consistent with an important role of B-RAF mutations in the pathogenesis of malignant melanoma.
The RAS-RAF-MEK-ERK signaling cascade regulates a wide variety of cellular processes, including proliferation, differentiation, and apoptosis (Peyssonnaux and Eychene, 2001; Smalley, 2003) . The importance of constitutive activation of this pathway for the maintenance of melanoma has been addressed by the specific targeting of kinases in melanoma cells in vitro and in xenotransplantation models. The potent MEK inhibitors CI 1040 and U0126 caused cell death when added to melanoma cell cultures (Collisson et al., 2003; Zhang et al., 2003) , and oral administration of CI 1040 led to rapid regression of lung metastases in mice (Collisson et al., 2003) . Similar results were observed when using the RAF inhibitor BAY43-9006 (Karasarides et al., 2004) . These data suggest that constitutive activation of the RAS-RAF-MEK-ERK signaling pathway could be a survival mechanism of melanoma cells. In a series of recent studies using RNA interference (RNAi), knockdown of B-RAF in melanoma cell lines induced apoptosis (Karasarides et al., 2004; Sumimoto et al., 2004) . However, the specific targeting of V600E B-RAF by RNAi produced highly varied phenotypic responses, including altered morphology, lower proliferation rates, and reduced anchorage-independent growth, but only rarely cell death (Hingorani et al., 2003; Sumimoto et al., 2004) . Furthermore, RNAimediated reduction of V600E B-RAF in A375mel melanoma cells only led to a modest reduction in tumorigenicity (Sumimoto et al., 2004) .
The basis for the conflicting results of RNAi experiments targeting B-RAF in melanoma is currently unknown. Here, we show that the majority of melanomas carrying the B-RAF V600E mutation have retained the wild type (WT) B-RAF allele, and that these cells can be rescued from the detrimental effects of losing mutated B-RAF by stimulation with growth factors, such as bFGF and HGF. The ability to propagate melanoma cells depleted of V600E B-RAF provides a convenient system for studying the efficacy and effects of RNAi.
Results

Mutational and allelic status of B-RAF in melanoma cell lines
To search for mutations in exon 15 of B-RAF and assess the mutated-to-WT B-RAF allele ratio, we analysed genomic DNA from 40 melanoma cell lines using polymerase chain reaction-denaturing gradient gel electrophoresis (PCR-DGGE). This method resolves mutated and WT DNA molecules on the basis of differences in melting temperature (see Figure 1 Figure 1 for example). The skewed distribution of mutated and WT B-RAF alleles is consistent with data obtained by comparative genomic hybridization analysis, showing that chromosome 7q, which includes the B-RAF locus, is frequently gained during melanoma progression (Bastian et al., 1998) .
Suppression of V600E
B-RAF induces cell death in FM55-M2 melanoma cells
To study the effects of V600E B-RAF on the growth and survival of melanoma cells, we generated two pSUPER expression constructs (Brummelkamp et al., 2002) designed to produce short hairpin RNAs (shRNAs) that selectively target either V600E B-RAF or WT B-RAF transcripts by RNAi (Hingorani et al., 2003) . These constructs were transfected into FM55-M2 melanoma cells, which harbor the V600E mutation and show a 1 : 1 ratio of mutated to WT B-RAF alleles (Figure 1 ). The cells reacted adversely to the transfection procedure, as evidenced by loss of cell anchorage and release of cytosolic lactate dehydrogenase (LDH) to the culture medium, irrespective of which construct was used. Nevertheless, cultures transfected with the construct targeting V600E B-RAF contained B30% fewer cells 48 h after transfection than mock-transfected cultures and cultures transfected with the construct targeting WT B-RAF (Figure 2a) , and the reduction in cell number was accompanied by a B50% higher release of LDH (Figure 2b) . Furthermore, in a colony formation assay, the number of G418-resistant colonies after transfection with the construct against V600E B-RAF was reduced B80% compared with mock transfectants (Figure 2c and d). There was no difference in the number of colonies between mock-transfected cultures and cultures transfected with the construct against WT B-RAF. Collectively, these data suggested that transfection of FM55-M2 cells with a construct targeting mutated V600E B-RAF induced cell death, which was not due to secondary effects of RNAi (Bridge et al., 2003; Sledz et al., 2003) . However, due to the extensive cell death observed in these transient transfections, we could not assess the specificity and efficacy of B-RAF suppression. To be able to study in more detail the cellular and molecular effects of B-RAF showed less or no knockdown, and these clones were excluded from further analysis. These experiments provided direct evidence that the shRNA-expressing constructs induced efficient and allele-specific suppression of WT and mutated B-RAF.
We also examined the levels of ERK1,2 activation in the clonal FM55-M2 cell lines 24 h after serum and bFGF withdrawal. Whereas ERK1,2 was constitutively activated in mock-transfected cells and cells targeted at WT B-RAF, the level of ERK1,2 activation was markedly reduced in cells depleted of Several growth factors other than bFGF have been implicated in proliferation and survival of melanocytes and/or melanoma development, including HGF, SCF, and ET-1 (Imokawa et al., 2000; Li et al., 2001; Satyamoorthy et al., 2001) . In a colony formation assay, 10 ng/ml human recombinant HGF was as effective as 100 ng/ml bFGF in rescuing FM55-M2 cells from the cell death induced by suppression of V600E B-RAF ( Figure 5) . Likewise, the combination of 100 ng/ml SCF and 10 ng/ml ET-1 increased the number of resistant clones transfected with the construct against V600E B-RAF to B50% of the number of mock-transfected clones ( Figure 5 ). This was slightly higher than the effect of 10 ng/ml ET-1 alone (B40%). In contrast, the effects of SCF alone, insulin-like growth factor 1 (IGF-1) and epidermal growth factor (EGF) were small and statistically insignificant, irrespective of the concentrations used ( Figure 5 , and data not shown), consistent with previous data showing that EGF does not have growth-promoting activity for melanocytes (Eisinger et al., 1985) and that SCF and IGF-1 do not contribute positively to the growth of late-stage melanomas (Huang et al., 1996; Satyamoorthy et al., 2001) . Rescue of V600E B-RAF knockdown in melanoma C Christensen and P Guldberg providing resistance to G418, and one targeting V600E B-RAF and providing resistance to puromycin (puro). As shown in colony formation assays, cells cotransfected with an empty G418 construct together with a puro construct targeting V600E B-RAF could be rescued by bFGF, consistent with the results described above. In contrast, cells targeted at both In another set of experiments, knockdown of both WT and mutated B-RAF was achieved through the use of a single construct that produces shRNA targeting a sequence common to both forms. In the absence of exogenous bFGF, transfections, of FM55-M2 cells with this construct resulted in as few colonies as transfections . The number of colonies was quantified after G418 selection, either in the absence of exogenous growth factors or in the presence of bFGF (100 ng/ml), HGF (10 ng/ml), IGF-1 (50 ng/ml), EGF (50 ng/ml), SCF (100 ng/ml), ET-1 (10 ng/ml), or SCF (100 ng/ml) and ET-1 (10 ng/ml). The data represent the mean7s.d. of at least three independent experiments performed in duplicate. Differences in the numbers of Mut-transfected colonies were evaluated for statistical significance using Student's paired t-tests. The reference value was the number of Mut-transfected colonies in the absence of growth factors. Data are presented with vector controls set at 100%. *Po0.05, **Po0.01
Rescue of V600E B-RAF knockdown in melanoma C Christensen and P Guldberg with the construct specifically targeting To investigate whether the ability of bFGF to rescue the effects of V600E B-RAF knockdown was specific for FM55-M2 cells, we examined two additional melanoma cell lines; FM82, which like FM55-M2 is heterozygous for the B-RAF V600E mutation, and SK-MEL-28, which harbors the V600E mutation but has lost the WT B-RAF allele (see Figure 1) . In agreement with our findings in FM55-M2, RNAi experiments led to reduced colony formation in FM82 cells when they were targeted at B-RAF led to reduced colony formation, but unlike the heterozygous cell lines FM55-M2 and FM82, this response could not be rescued by bFGF (Figure 6d ). These data provide further evidence that the rescue of V600E B-RAF knockdown by exogenous bFGF involves signaling through WT B-RAF.
As shown in Figure 5 , growth factors other than bFGF were able to sustain the growth of FM55-M2 cells targeted at V600E B-RAF. Notably, HGF appeared as efficient as bFGF in this respect. We, therefore, tested the effect of exogenous HGF on To study in more detail the effects of B-RAF knockdown, we examined the clonal cultures of FM55-M2 cells stably transfected with shRNA-producing constructs and propagated in the presence of bFGF (see Figure 4) . No effects of bFGF withdrawal were observed in mock-transfected cells or cells targeted at WT B-RAF (Figure 7a , and data not shown). By contrast, marked morphological changes were observed in cultures of cells depleted of V600E B-RAF. After 4 days of growth in bFGF-free medium, some cells shrank and detached, whereas others displayed a flattened, circular shape. The number of cells showing either of these changes increased over time, and cell death was extensive after 6 days of bFGF withdrawal (Figure 7a ). Assessment of cell lysis was made by measuring the release of LDH (Figure 7b and c) . Since the medium with or without bFGF was replaced every 48 h, the data points represent total LDH release in distinct 48-h intervals. Between 6 and 8 days after removal of bFGF, total LDH release had reached R constructs. The number of colonies was quantified after three weeks of selection in the absence or presence of bFGF (100 ng/ml) or HGF (10 ng/ml). G418 R , empty pSuper/G418 R construct; PURO R , empty pSuperior/ PURO R construct
Rescue of V600E B-RAF knockdown in melanoma C Christensen and P Guldberg 20-30%, whereas it remained o5% in cultures grown in the presence of bFGF (Figure 7b ). Removal of exogenous bFGF did not induce any changes in cell lysis in mock-transfected cultures or cultures targeted at WT B-RAF (Figure 7c ). These experiments are likely to underestimate the total extent of cell death, considering that LDH is released only from late-apoptotic cells with disrupted plasma membranes.
Staining with Hoechst/Sytox revealed the presence of late-apoptotic cells with condensed nuclei and permeable cell membranes in Mut #1 and Mut #2 cultures deprived of bFGF (Figure 8 ). By contrast, the flat symmetrical cells emerging in these cultures remained adherent and viable, did not stain with Sytox, and did not contain condensed nuclei (Figure 8 ). These cells stained strongly for senescence-associated b-galactosidase (SA-b-Gal) (Figure 8 ) and showed no signs of proliferative activity even after 14 days of incubation in the absence of exogenous bFGF (Figure 9a ), suggesting that they had entered senescence-like growth arrest. In summary, FM55-M2 cells with reduced levels of V600E B-RAF required exogenous bFGF to be propagated and underwent apoptosis or senescence-like growth arrest when deprived of this growth factor.
While the vast majority of cells in Mut #1 and Mut #2 cultures underwent apoptosis or senescence-like growth arrest upon bFGF withdrawal, large colonies appeared in each of these cultures, containing cells that were morphologically similar to control cells (Figure 9a ). These cells could readily be expanded in the absence of exogenous bFGF and showed growth rates similar to control cells (data not shown). RT-PCR-DGGE analysis of B-RAF transcripts showed that these cells reexpressed V600E B-RAF (Figure 9b ), providing additional evidence that the phenotypic changes observed in all other cells in these cultures could be ascribed to depletion of V600E B-RAF.
Discussion
The importance of constitutive activation of RAS-RAF-MEK-ERK signaling for sustained growth and survival of melanoma cells in vitro and in vivo has been demonstrated in studies using inhibitors of RAF or MEK (Collisson et al., 2003; Zhang et al., 2003; Karasarides et al., 2004) . Moreover, a series of studies using RNAi to ablate specific components of this pathway have shown that B-RAF is required for constitutive MEK-ERK signaling in melanoma cells harboring the common oncogenic version of this kinase, V600E B-RAF (Hingorani et al., 2003; Karasarides et al., 2004; Sumimoto et al., 2004; Wellbrock et al., 2004b) . While depletion of total B-RAF in melanoma cell lines consistently led to apoptosis (Hingorani et al., 2003; Karasarides et al., 2004) , RNAi specifically targeting V600E B-RAF led to a variety of phenotypes, ranging from apoptosis in some cell lines (Hingorani et al., 2003) , to altered morphology, lower proliferation rates, and reduced anchorage-independent growth in other cell lines (Sumimoto et al., 2004) . It is unclear whether the less severe phenotypes observed in some melanoma cell lines targeted at V600E B-RAF may result from a low efficiency of RNAi, and whether apoptosis in other cell B-RAF led to a B80% reduction in colony formation. These cell lines, like the majority of cell lines examined in this study, had retained the WT B-RAF allele. As shown in the colony formation assay, bFGF, HGF and, to a lesser extent, ET-1 were all capable of rescuing V600E B-RAF knockdown, consistent with a role of these growth factors as potent proliferation and survival factors for melanocytic cells (Halaban, 2000) . Notably, clones of FM55-M2 cells stably producing shRNAs against either V600E B-RAF or WT B-RAF could be propagated in the presence of bFGF, and the ratio of The ability to propagate individual clones with efficient knockdown of V600E B-RAF provided a convenient model for studying the effects of this oncogene on proliferation and survival of melanoma cells. Upon withdrawal of bFGF from FM55-M2 melanoma cells depleted of V600E B-RAF, we observed two distinct phenomena, which accounted for virtually all cells in these cultures. The predominant response was apoptosis, as evidenced by a majority of cells with condensed nuclei and by a high release of LDH. The second type of response was senescence-like growth arrest characterized by increased expression of SA-b-Gal (Dimri et al., 1995) . Considering that RNAi-based knockdown of V600E B-RAF in these cells spared the corresponding WT allele, it is likely that the cellular responses observed in these experiments are due to loss of V600E B-RAF rather than loss of a normal, indispensable B-RAF function. The molecular basis for the two different responses to bFGF withdrawal in FM55-M2 cells with low levels of V600E B-RAF is unclear and awaits further studies. One possible explanation is that the level of V600E B-RAF differed in these cells despite their clonal origin. Previous studies have shown that the activity of RNA polymerase III varies throughout the cell cycle (Sutcliffe et al., 2000; Scott et al., 2001) , suggesting that the production of shRNA from the H1 promoter of the pSUPER construct and, accordingly, the level of RNAi-mediated suppression may also vary in a cell cycle-dependent manner. Alternatively, the cellular response to growth factor withdrawal may in itself be cell cycle dependent.
The human RAF kinase family has three members: A-RAF, B-RAF, and C-RAF (also called Raf-1) (Wellbrock et al., 2004a) . These proteins share a common structure and are expressed in a wide range of tissues, although the highest expression of B-RAF is found in neuronal tissues (Storm et al., 1990 (Pritchard et al., 1995; Huser et al., 2001; Mercer et al., 2002) .
The importance of B-RAF in melanoma development and the high frequency of the V600E B-RAF mutation makes B-RAF an obvious therapeutic target Garnett and Marais, 2004) . Although the kinase inhibitor BAY43-9006, which inhibits both B-RAF and C-RAF, induces apoptosis in cultured melanoma cells and provides some therapeutic benefit in xenotransplantation models (Karasarides et al., 2004) , specific targeting of V600E B-RAF may be considered advantageous in terms of fewer side effects. However, it sounds a note of caution that naturally occurring growth factors, as shown in this study, can modulate the effect of V600E B-RAF knockdown by signaling through WT B-RAF. The cutaneous microenvironment is known to contain various growth factors, including bFGF, HGF, and endothelins , and autocrine mechanisms involving bFGF or HGF contribute to RAS-RAF-MEK-ERK signaling in melanoma cells, even those harboring V600E B-RAF . Accordingly, conditions may be present in vivo that allow melanoma cells to bypass silencing of their oncogenic B-RAF allele. Consistent with this hypothesis, knockdown of V600E B-RAF in A375mel melanoma cells, which have retained WT B-RAF, only led to a minor decrease in the rate of tumor growth, while the effect of reducing total B-RAF levels was much greater (Sumimoto et al., 2004) . Although V600E B-RAF is still a promising target for melanoma therapy, the possible influence of tumor microenvironment and autocrine regulatory networks should be considered.
Materials and methods
Cell lines and culture
FM melanoma cell lines were established as described previously (Guldberg et al., 1997) . The SK-MEL-3, 
DNA isolation and mutation analysis
Genomic DNA was isolated using the Purescript DNA Isolation Kit (Gentra Systems). B-RAF mutations were detected using a combination of PCR and DGGE. Primer sequences for B-RAF exon 15 were 5 0 -[CGCCCGCCGCGC CCCGCGCCCGTCCCGCCGCCCCCGCCCG]-TTTTCCT TTACTTACTACACCTC-3 0 and 5 0 -GGAAAAATAGCCT CAATTCT-3 0 , which generate a 207-bp product. PCR was performed in 25-ml volumes containing 1 Â buffer and 1 U of Taq polymerase (HotStarTaq Kit, Qiagen), 0.2 mM cresol red, 12% sucrose, 10 pmol of each primer, 100 mM each dNTP, and 50 ng of DNA. Reactions were started by denaturation at 951C for 15 min, followed by 35 cycles at 951C for 20 s, 561C for 30 s, and 721C for 30 s. In all 10 ml of the GC-clamped product was loaded onto a 10% denaturant/6% polyacrylamide-70% denaturant/12% polyacrylamide double-gradient gel. The gels were run at 170 V for 5 h in 1 Â TAE buffer kept at a constant temperature of 551C, stained in 1 Â TAE buffer containing ethidium bromide (2 mg/ml), and photographed under UV transillumination. A TIFF-format image of the gel was generated, and the intensities of the two homoduplex bands were determined using the 1D Gel Analysis Phoretix Software (Phoretix, Newcastle, UK). Direct sequencing of doublestranded PCR-products was performed with a 33 P-end-labeled primer using the ThermoPrime Cycle Sequencing Kit (Amersham). For resolution of mutated B-RAF transcripts, cDNA was synthesized from total RNA (1 mg) using oligo-dT primers and Superscript III (Invitrogen), and subsequently PCRamplified using primers 5 0 -[CGCCCGCCGCGCCCCGCG CCCGTCCCGCCGCCCCCGCCCGATTATTTATTAT]-GT CAATCATCCACAGAGACC-3 0 and 5 0 -ACTGTTCAAACT GATGGGAC-3 0 to generate a 181-bp product from exon 14 to exon 15. PCR and DGGE conditions were as described above.
Plasmid constructs
An shRNA expression vector, pSUPER (Brummelkamp et al., 2002) , was modified to allow stable transfection under G418 selection (pSUPER/G418 R ). This was performed by ligating a fragment released from the pcDNA3.1/neo R vector (Invitrogen) by digestion with PmeI and AflIII into pSUPER digested with HincII and AflIII. This fragment contained the neomycin resistance gene under the control of an SV40 promoter. When indicated, another shRNA expression vector encoding puromycin resistance (pSuperior/PURO R ; Oligoengine) was applied. The sequence targeting WT B-RAF was formed from duplex DNA consisting of 5 0 -gatccccGCTACAGTGAAA TCTCGATttcaagagaATCGAGATTTCACTGTAGCtttttgga aa-3 0 (sense) and 5 0 -agcttttccaaaaaGCTACAGTGAAATCTC GATtctcttgaaATCGAGATTTCACTGTAGCggg-3 0 (antisense). The sequences in capitals are B-RAF-specific. The sequence targeting V600E B-RAF was GCTACAGAGAAATCTCGAT, and the sequence common to both WT and mutated B-RAF was GAGAAGAAACCAATTGGTT. The duplex DNA was cloned into the Bgl II and Hind III sites of pSUPER/G418 R or pSuperior/PURO R .
Transfection and colony formation assay
Cells were seeded in six-well plates (8 Â 10 5 cells/well) the day before transfection. At 4 h before transfection, the medium was replaced with fresh medium containing growth factors, as indicated. Transfections were performed with 2.0 mg of plasmid and 8 ml of Lipofectamine 2000, according to the manufacturer's instructions (Invitrogen). For cotransfections, 1.0 mg of each plasmid was used. The day after transfection, cells were plated at a lower density (10 4 cells/cm 2 for single transfections, and 10 5 cells/cm 2 for cotransfections) and incubated overnight, and the medium was then substituted with medium containing antibiotics (500 mg/ml G418 for single transfections, or 500 mg/ml G418 and 0.5 mg/ml puromycin for cotransfections). The cells were grown for 3 weeks with fresh medium added every second day, containing the appropriate antibiotics and, when indicated, growth factors. Colonies were fixed with a solution of 60% acetone and 3% formaldehyde in HEPES-buffered saline, and subsequently stained with a solution of 0.1% crystal violet and 20% methanol. Three independent experiments were made. Data were analysed for variance and evaluated for significance using Student's paired t-tests.
LDH assay
Cell death was assessed by determining the release of LDH into the culture medium, using the Cytotoxicity Detection Kit (Roche). The substrate was mixed with an equal volume of culture supernatant (S) or total lysate from the remaining cell monolayer (C) after lysis with 1% Triton X-100. The percentage LDH release was calculated as S/(S þ C). Three independent experiments were carried out.
Hoechst/Sytox staining
Cultures were stained with a mixture of the membrane permeant dye H-33342 (500 ng/ml) (Sigma-Aldrich) and the membrane impermeant dye Sytox (500 nM) (Molecular Probes). Cells were classified as being necrotic (damaged cell membrane, noncondensed nuclei), apoptotic (intact cell membrane, condensed or fragmented nuclei), or late apoptotic undergoing secondary necrosis (damaged cell membrane, condensed or fragmented nuclei).
Immunoblot analysis of ERK1,2
Cells were washed twice with serum-free DME/F12 medium and incubated in this medium. The following day, cells were washed again, and 2 h later they were incubated in the same medium containing 100 ng/ml bFGF. Lysates were produced by scraping off the cells in the presence of extraction buffer (50 mM Tris Cl pH 7.6, 5 mM EDTA, 150 mM NaCl, 10% glycerol, 1% Triton X-100) supplemented with a protease inhibitor cocktail (Sigma-Aldrich). The protein content was measured using the Coomassie Plus Protein Assay Reagent (Pierce), and 50 mg protein was separated on NuPage 4-12% Bis-Tris polyacrylamide gels (Invitrogen). Phosphorylated (Thr202/Tyr204) and nonphosphorylated ERK1,2 were detected by immunoblotting using the PhosphoPlus p44/42 MAPK Antibody Kit (Cell Signaling).
